News Corcept Therapeutics Incorporated

Equities

CORT

US2183521028

Real-time Estimate Cboe BZX Other stock markets 12:13:30 2024-06-06 pm EDT			5-day change	1st Jan Change
34.5 ^USD	+0.17%		+9.80%	+5.51%

Jun. 04	Truist Adjusts Price Target on Corcept Therapeutics to $65 From $44, Maintains Buy Rating	MT
May. 28	Sector Update: Health Care Stocks Retreat Tuesday Afternoon	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Groundbreaking Study by MAIA Biotechnology (NYSE: MAIA) Indicates Promising New Treatment for Advanced Lung Cancer	07:20am	AQ
Truist Adjusts Price Target on Corcept Therapeutics to $65 From $44, Maintains Buy Rating	Jun. 04	MT
Corcept Therapeutics Announces Presentations of Results of Pivotal Phase 3 GRACE Trial Evaluating Relacorilant in Patients with Hypercortisolism (Cushing’s Syndrome)	Jun. 03	GL
Corcept Announces Primary Endpoint Met in Pivotal Phase 3 GRACE Trial of Relacorilant in Patients with Hypercortisolism	May. 29	AQ
Sector Update: Health Care Stocks Retreat Tuesday Afternoon	May. 28	MT
Corcept Therapeutics Says Phase 3 Hypercortisolism Trial Meets Primary Endpoint; Shares Advance	May. 28	MT
Corcept Announces Primary Endpoint Met in Pivotal Phase 3 GRACE Trial of Relacorilant in Patients With Hypercortisolism (Cushing’s Syndrome)	May. 28	GL
Corcept Announces Primary Endpoint Met in Pivotal Phase 3 GRACE Trial of Relacorilant in Patients With Hypercortisolism (Cushing’s Syndrome)	May. 28	AQ
Corcept Announces Primary Endpoint Met in Pivotal Phase 3 Grace Trial of Relacorilant in Patients with Hypercortisolism (Cushing?S Syndrome)	May. 28	CI
Corcept Therapeutics Insider Sold Shares Worth $1,400,000, According to a Recent SEC Filing	May. 16	MT
Truist Lifts Corcept Therapeutics' PT to $44 From $42 After Raised Kolym Guidance, Keeps Buy Rating	May. 02	MT
Earnings Flash (CORT) CORCEPT THERAPEUTICS INCORPORATED Reports Q1 EPS $0.25, vs. Street Est of $0.22	May. 01	MT
Transcript : Corcept Therapeutics Incorporated, Q1 2024 Earnings Call, May 01, 2024	May. 01
Corcept: Q1 Earnings Snapshot	May. 01	AQ
Corcept Therapeutics Incorporated Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 01	CI
Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update	May. 01	GL
Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update	May. 01	AQ
Corcept Completes Enrollment in Phase 4 CATALYST Trial	Apr. 29	GL
Corcept Therapeutics Incorporated Completes Enrollment in Phase 4 Catalyst Trial	Apr. 29	CI
Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call	Apr. 24	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Corcept Therapeutics Incorporated

Equities

CORT

US2183521028

Summary

Filters